Brief: Caris Life Sciences And Xencor Expand Target Discovery Collaboration For XMAB
05/01/2023 11:32
Jan 5 (Reuters) - Xencor Inc XNCR.O :
* CARIS LIFE SCIENCES AND XENCOR EXPAND TARGET DISCOVERY
COLLABORATION FOR NOVEL XMAB® ANTIBODY DRUG CANDIDATES
* XENCOR - UNDER TERMS OF NEW DEAL, CARIS TO RECEIVE UPFRONT
PAYMENT AND ELIGIBLE TO RECEIVE UP TO $187 MILLION IN
DEVELOPMENT, COMMERCIAL MILESTONE PAYMENTS
Source text for Eikon: ID:nPn9gTF2Ha
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates